Others titles

  • MD Premarket Approval in the United States
  • Medical Device Premarket Approval

Keywords

  • Premarket Approval
  • PMA Approvals
  • US Premarket
  • FDCA
  • FDA Device
  • CDRH and Applicants
  • CDRH’s Post-Approval Studies
  • Post-Approval Studies
  • Meical Devices
  • Post-Approval Device

FDA Premarket Approval Database

Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. Due to the level of risk associated with Class III devices, FDA has determined that general and special controls alone are insufficient to assure the safety and effectiveness of class III devices. Therefore, these devices require a premarket approval (PMA) application under section 515 of the FD&C Act in order to obtain marketing clearance.

Log in to download
Complexity

Get The Data

For getting access to data download links please read and accept the end-user license agreement.
Your Data License
  • Research
    Non-Commercial, Share-Alike, Attribution Free Forever
  • Commercial
    Commercial Use, Remix & Adapt, White Label Log in to download

John Snow Labs Standard End User License Agreement

Last updated:January 20, 2021

This Data Library End User License Agreement (“EULA”) applies to academic researchers, educators, and students using any product of John Snow Labs in John Snow Labs’ Data Library as defined below (hereinafter referred to “you”). This EULA is between you and John Snow Labs Inc., a Delaware corporation (“John Snow Labs”, “we” or “us”).

By downloading and/or using (as applicable) Data Library of John Snow Labs (as defined below), you automatically agree to be bound by, and use it in compliance with, this EULA. This EULA, together with additional terms and conditions and/or policies referenced herein or located on https://www.johnsnowlabs.com and/or conveyed to you by John Snow Labs, is a legally binding contract between you and John Snow Labs.

PLEASE READ THIS EULA CAREFULLY BEFORE DOWNLOADING OR USING DATA LIBRARY.

We may make changes to this EULA from time to time. When we do so, we will revise the “last updated” date given above. The then-current version of this EULA will supersede all earlier versions. You agree that your continued use of Data Library after such changes have been published to our EULA will constitute your acceptance of such revised EULA.

Definitions

“Data Library” means a data library provided by John Snow Labs and located at https://www.johnsnowlabs.com/marketplace/;

“Website” means https://www.johnsnowlabs.com being owned and operated by John Snow Labs.

Important Notice

By downloading and using any product from the Data Library, you acknowledge that the use of Data Library can be subject to the restrictions and controls imposed by United States export regulations.

You represent and warrant that you do not intend to use Data Library for any purpose prohibited by United States export regulations, including, without limitation, terrorism, cyber-attacks, cyber-crimes, money-laundering, industrial espionage, or nuclear, chemical or biological weapons proliferation. Further, you represent and warrant that you are not listed as a denied party on any list governing United States exports.

Eligibility

Our Data Library can be used by an individual.

In the event you have entered into a separate written agreement with John Snow Labs regarding Data Library that contemplates terms that are inconsistent with this EULA, the written agreement shall control and this EULA will not apply to you to the extent inconsistent with such written agreement, or, if such written agreement is contemplated to be in lieu of this EULA, then this EULA shall not apply at all

License Granted

Subject to your compliance with this EULA, as well as any other applicable policies, John Snow Labs grants you non-exclusive, non-transferable, revocable, license to download, access to, modify, and use of, Data Library worldwide (subject to applicable export laws) during the term of this EULA (as described below) under the following conditions:

  • The license can be used solely for research, private study and personal use of Data Library for unlimited period, or unless terminated under this EULA.were made;
  • This license is personal to you and is limited by all terms and conditions set forth in this EULA;
  • The license is granted as a non-commercial, attribution, share-alike and no-derivate-work license as more detailed below;
  • Under the attribution license, you must give the appropriate name of the creator and a copyright notice of John Snow Labs, provide link to this license and indicate if changes
  • Under the share-alike license, you can distribute modified works only under a license identical to this EULA;
  • Under the no-derivate-work license, you can perform only verbatim copies of Data Library, not derivate works or remixes based on it;
  • If the license is used for academic research purpose, the publication shall be made under the open-access, open-source and open-data license.

You can download any dataset from the Data Library from the Website.

Except for your pre-existing rights and this license granted to you, we and our licensors retain all rights, titles and interests in and to our Data Library, all related intellectual property rights, including trademarks (whether registered or pending), domain and business names. Our Data Library is protected by applicable intellectual property laws, including United States copyright law and international treaties.

John Snow Labs is entitled to revoke the license granted at any time at its sole discretion.

License Restrictions

You will be deemed to have taken any action that you permit, assist or facilitate any person or entity to take related to this EULA, your content or use of Data Library. You are responsible for end users’ use of your content and Data Library. You will ensure that all end users comply with your obligations under this EULA and that the terms of your agreement with each end user are consistent with this EULA. If you become aware of any violation of your obligations under this EULA caused by an end user, you will immediately suspend access to your content and Data Library by such end user.

License Restrictions

You will access or use our Data Library solely via John Snow Labs’ Data Library.

Except as otherwise explicitly provided in this EULA or as may be expressly permitted by applicable law, you will not, and will not permit or authorize any third party to:

  1. you cannot reproduce, translate, enhance, decompile, disassemble, reverse engineer or create derivative works of Data Library or its technological features or measures;
  2. you cannot rent, lease, sell, resell, loan, distribute, or sublicense access to any of Data Library;
  3. you cannot circumvent or disable any security or technological features or measures of Data Library;
  4. you cannot use our intellectual property rights without our express prior written authorization or in violation of this EULA;
  5. you cannot use Data Library with an intent to build a competitive product or service, or copy or substantially copy any ideas, features, functions, organization, structure, application program interface, graphics, or user interface of Data Library;
  6. you cannot copy, distribute, or resell any of the information; audio, visual, and audiovisual works, or other content made available on Data Library (collectively, “Content”) or compile or collect any Content as part of a database or other work;
  7. you cannot use any automated tool (e.g., robots, spiders) to access or use Data Library, or to store, copy, modify, distribute, or resell any Content;
  8. you cannot circumvent or disable any rights management, usage rules, or other security features of Data Library;
  9. you cannot use Data Library in a manner that overburdens, or that threatens the integrity, performance, or availability of, Data Library; or
  10. you cannot remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of Data Library or any Content.

If you breach any of this EULA, the above license will terminate automatically.

Fees and Taxes

This license is for non-commercial use. If you wish to use our Data Library for commercial use, please contact us at support@JohnSnowLabs.com.

Support and Updates

Under this EULA, support services are excluded.

From time to time John Snow Labs can perform updates to our software. If available, such updates may include bug fixes, new features and/or enhancements. You are solely responsible for deploying such updates at your own risk and liability.

Term and Termination

This EULA will become effective as of the date of your order of Data Library and shall be in effect until terminated.

John Snow Labs may suspend or terminate your right to use Data Library, if you or your end user’s use of Data Library:

  1. is in breach of this EULA;
  2. poses a security risk to Data Library;
  3. could adversely impact our systems, Data Library or other customers;
  4. could subject us, our affiliates, or any third party to liability; or
  5. could be fraudulent.

We may also suspend or terminate your right to use Data Library, if you have ceased to operate in the ordinary course, made an assignment for the benefit of creditors or similar disposition of your assets, or become the subject of any bankruptcy, reorganization, liquidation, dissolution or similar proceeding.

You will cease use of Data Library during any period of suspension, or upon termination of this EULA.

All provisions which by their nature are intended to survive termination shall survive termination of this EULA.

Access to Data Library

We do not provide you with the equipment to access Data Library. You are responsible for all fees charged by third parties related to your access and use of Data Library (e.g., charges by Internet service providers).

You are responsible for monitoring your use of Data Library, including payment of all fees and/or taxes related to such access and use. You agree that John Snow Labs is permitted to request and you hereby consent to provide John Snow Labs information related to your use of Data Library for auditing purposes.

You also certify that you are legally permitted to use Data Library, and take full responsibility for the selection and use of Data Library. This EULA is void where prohibited by law, and the right to use Data Library is revoked in such jurisdictions. John Snow Labs makes no claim that Data Library may be lawfully used outside of the United States. If you use Data Library from outside of the United States, you do so at your own risk and you are responsible for compliance with the laws of jurisdiction.

Privacy Policy

We may collect, store and receive personal and other information about you through our Products. Our collection and use of this information is governed by our Privacy Policy available at https://www.JohnSnowLabs.com/privacy/ which may be amended from time to time.

Links and Third Party Content

Data Library may display, or contain links to, third party products, services, and websites. Any opinions, advice, statements, services, offers, or other information that constitutes part of the content expressed, authored, or made available by other users or other third parties, or which is accessible through or may be located using Data Library (collectively, “Third Party Content”) are those of the respective authors or producers and not of us or our shareholders, directors, officers, employees, agents, or representatives.

We do not control Third Party Content and do not guarantee the accuracy, integrity or quality of such Third Party Content. We are not responsible for the performance of, we do not endorse, and we are not responsible or liable for, any Third Party Content or any information or materials advertised in any Third Party Content. By using Data Library, you may be exposed to content that is offensive, indecent, or objectionable. We are not responsible or liable, directly or indirectly, for any damage or loss caused to you by your use of or reliance on any goods, services, or information available on or through any third party service or Third Party Content. It is your responsibility to evaluate the information, opinion, advice, or other content available on and through our Products.

Proprietary Rights

John Snow Labs will not obtain any rights under this EULA from you (or your licensors) to your content.

Data Library is and remains the exclusive property of John Snow Labs and its licensors. Except for the access and use rights expressly set forth in this EULA, no license or other rights in or to Data Library or John Snow Labs trademark(s) and other intellectual property rights therein, are granted to you, and all such licenses and rights are expressly reserved. You will not remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of Data Library or any Content.

Trademarks

“John Snow Labs,” the John Snow Labs logo, and any other product, business or service name or slogan, whether registered or pending, displayed on Data Library are trademarks of John Snow Labs, Inc. or its suppliers or licensors, and may not be copied, imitated or used, in whole or in part, without the prior written permission of John Snow Labs or the applicable trademark holder. You may not use any metatags or any other “hidden text” utilizing “John Snow Labs” or any other name, trademark or product, business or service name of John Snow Labs without our prior written permission. In addition, the look and feel of Data Library, including all page headers, custom graphics, button icons and scripts, is the service mark, trademark and/or trade dress of John Snow Labs may not be copied, imitated or used, in whole or in part, without our prior written permission. All other trademarks, pending trademarks, registered trademarks, product names and company names or logos mentioned in Data Library are the property of John Snow Labs Inc. and/or their respective owners. Reference to any products, services, processes or other information, by trade name, trademark, manufacturer, supplier, or otherwise does not constitute or imply endorsement, sponsorship, or recommendation thereof by us.

Disclaimer of Warranties

YOUR USE OF DATA LIBRARY IS AT YOUR SOLE RISK. THE PRODUCTS AND CONTENT EACH ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. WE AND OUR SUPPLIERS AND LICENSORS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT. WE DO NOT GUARANTEE THE ACCURACY, COMPLETENESS, OR USEFULNESS OF THE PRODUCTS OR ANY CONTENT, AND YOU RELY ON THE PRODUCTS AND CONTENT AT YOUR OWN RISK. ANY MATERIAL THAT YOU ACCESS OR OBTAIN THROUGH OUR PRODUCTS IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY MATERIAL THROUGH OUR PRODUCTS. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM US OR THROUGH OR FROM OUR PRODUCTS WILL CREATE ANY WARRANTY NOT EXPRESSLY STATED IN THIS EULA. SOME STATES MAY PROHIBIT A DISCLAIMER OF WARRANTIES AND YOU MAY HAVE OTHER RIGHTS THAT VARY FROM STATE TO STATE.

Limitation of Liability

WE AND OUR SUPPLIERS AND LICENSORS WILL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA, OR OTHER INTANGIBLE LOSSES (EVEN IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF THESE DAMAGES), RESULTING FROM YOUR USE OF OUR PRODUCTS AND CONTENT. UNDER NO CIRCUMSTANCES WILL THE TOTAL LIABILITY OF US AND OUR SUPPLIERS AND LICENSORS OF ALL KINDS ARISING OUT OF OR RELATED TO YOUR USE OF THE PRODUCTS AND CONTENT (INCLUDING BUT NOT LIMITED TO WARRANTY CLAIMS), REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR OTHERWISE, EXCEED THE AMOUNTS, IF ANY, THAT YOU HAVE PAID FOR YOUR USE OF THE PRODUCTS AND CONTENT. BECAUSE SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY TO YOU.

Indemnity

To the full extent permitted by applicable law, you shall defend, indemnify and hold harmless John Snow Labs, its affiliates and its licensors, and each of their respective employees, officers, directors, and representatives from and against any claims, damages, losses, liabilities, costs, and expenses (including reasonable attorney’s fees) arising out of or relating to any third party claim concerning: (a) your use of Data Library; (b) breach of this EULA or violation of applicable law by you; (c) any content or the combination of such content with other software, content or processes, including any claim involving alleged infringement or misappropriation of third-party rights by such content or combination; or (d) breach of any obligation or duty you owe to a third party.

Legal Notices

Enforcement of this EULA will be governed by the laws of the State of Delaware, excluding its conflict and choice of law principles. The exclusive jurisdiction and venue for any claims arising out of or related to this EULA or your use of Data Library will lie in the state and federal courts located in Sussex County, within the State of Delaware, and you irrevocably agree to submit to the jurisdiction of such courts. Our failure to enforce any right or provision in this EULA will not constitute a waiver of such right or provision unless acknowledged and agreed by us in writing. In the event that a court of competent jurisdiction finds any provision of this EULA to be illegal, invalid, or unenforceable, the remaining provisions will remain in full force and effect.

Notifications

We may use your contact information to notify you if we have any legitimate interest or if we need to notify you on any important information related to your use of Data Library. We will not send you newsletters unless you expressly consented to such notifications.

Contacting Us

If you have any questions or concerns about Data Library or this EULA, you may contact us by email at support@JohnSnowLabs.com.

Description

PMA is the most stringent type of device marketing application required by FDA. The applicant must receive FDA approval of its PMA application prior to marketing the device. PMA approval is based on a determination by FDA that the PMA contains sufficient valid scientific evidence to assure that the device is safe and effective for its intended use(s). An approved PMA is, in effect, a private license granting the applicant (or owner) permission to market the device. The PMA owner, however, can authorize use of its data by another.

The PMA applicant is usually the person who owns the rights, or otherwise has authorized access, to the data and other information to be submitted in support of FDA approval. This person may be an individual, partnership, corporation, association, scientific or academic establishment, government agency or organizational unit, or other legal entity. The applicant is often the inventor/developer and ultimately the manufacturer.

FDA regulations provide 180 days to review the PMA and make a determination. In reality, the review time is normally longer. Before approving or denying a PMA, the appropriate FDA advisory committee may review the PMA at a public meeting and provide FDA with the committee’s recommendation on whether FDA should approve the submission. After FDA notifies the applicant that the PMA has been approved or denied, a notice is published on the Internet (1) announcing the data on which the decision is based, and (2) providing interested persons an opportunity to petition FDA within 30 days for reconsideration of the decision.

About this Dataset

Data Info

Date Created

2013

Last Modified

2020-10-15

Version

2020-10-15

Update Frequency

Monthly

Temporal Coverage

1960 to 2020-10-15

Spatial Coverage

United States

Source

John Snow Labs; Food and Drug Administration (FDA);

Source License URL

Source License Requirements

N/A

Source Citation

N/A

Keywords

Premarket Approval, PMA Approvals, US Premarket, FDCA, FDA Device, CDRH and Applicants, CDRH’s Post-Approval Studies, Post-Approval Studies, Meical Devices, Post-Approval Device

Other Titles

MD Premarket Approval in the United States, Medical Device Premarket Approval

Data Fields

Name Description Type Constraints
PMA_NumberPremarket Approval Numberstring-
Supplement_NumberPMA Supplement Numberstring-
ApplicantThe Name of the applicantstring-
Address_Line_1The Address of the applicantstring-
Address_Line_2Second part of the Address of the applicantstring-
CityThe City of the applicantstring-
State_AbbreviationThe State of the applicantstring-
Zip_CodeThe Zip code of the applicantstring-
Zip_ExtensionThe zip code extension of the applicantstring-
Generic_NameGeneric Name of the productstring-
Trade_NameTrade Name of the productstring-
Product_CodeProduct Code Classificationstring-
Advisory_CommitteeAdvisory Committeestring-
Supplement_TypeType of Supplementstring-
Supplement_ReasonPrimary Reason for Supplementstring-
Is_Review_GrantedExpedited Review Grantedstring-
Received_DateDate Receiveddate-
Decision_DatePMA date decisiondate-
Docket_NumberDocket numberstring-
Fed_Reg_Notice_DateDate of federal register noticedate-
Decision_CodeFDA decision codestring-
Approval_Order_StatementFDA approval order statementstring-

Data Preview

PMA NumberSupplement NumberApplicantAddress Line 1Address Line 2CityState AbbreviationZip CodeZip ExtensionGeneric NameTrade NameProduct CodeAdvisory CommitteeSupplement TypeSupplement ReasonIs Review GrantedReceived DateDecision DateDocket NumberFed Reg Notice DateDecision CodeApproval Order Statement
P160006VENTANA MEDICAL SYSTEMS, INC.1910 EAST INNOVATION PARK DR.TUCSONAZ85755Immunohistochemistry assay, antibody, programmed death-ligand 1VENTANA PD-L1 (SP142) AssayPLSPATrue2016-02-222016-10-1816M-34312016-11-15APCBApproval for the VENTANA PD-L1 (SP142) Assay. This device is indicated for the following: VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma and non-small cell lung cancer (NSCLC) tissue stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a VENTANA BenchMark ULTRA instrument. Determination of PD-L1 status is indication-specific, and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.PD-L1 expression in 5% IC determined by VENTANA PD-L1 (SP142) Assay in urothelial carcinoma tissue is associated with increased objective response rate (ORR) in a non-randomized study of TECENTRIQ (atezolizumab).PD-L1 expression in 50% TC or 10% IC as detected by VENTANA PD-L1 (SP142) Assay in NSCLC may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).
P150047Roche Molecular Systems, Inc.4300 Hacienda DrivePleasantonCA945882722.0Somatic gene mutation detection systemcobas EGFR MUTATION TEST v2OWDPATrue2015-12-092016-06-0116M-14592016-06-06APCBApproval for the cobas EGFR Mutation Test v2 is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived from EDTA anti-coagulated peripheral whole blood.The test is indicated as a companion diagnostic to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 below in accordance with the approved therapeutic product labeling.Table 1 Drug FFPET PlasmaTARCEVA (erlotinib) Exon 19 deletions and L858R Exon 19 deletions and L858RTAGRISSO (osimertinib) T790M Patients with positive cobas EGFR Mutation Test v2 test results using plasma specimens for the presence of EGFR exon 19 deletions or L858R mutations are eligible for treatment with TARCEVA (erlotinib). Patients who are negative for these mutations by this test should be reflexed to routine biopsy and testing for EGFR mutations with the FFPET sample type.Drug safety and efficacy have not been established for the EGFR mutations listed in Table 2 below that are also detected by the cobas EGFR Mutation Test v2. Table 2 Drug FFPET PlasmaTARCEVA (erlotinib) G719X, exon 20 insertions, T790M, S768I and L861Q G719X, exon 20 insertions, T790M, S768I and L861QTAGRISSO (osimertinib) G719X, exon 19 deletions, L858R, exon 20 insertions, S768I, and L861Q G719X, exon 19 deletions, L858R, exon 20 insertions, T790M, S768I, and L861QFor manual sample preparation, FFPET specimens are processed using the cobas DNA Sample Preparation Kit and plasma specimens are processed using the cobas cfDNA Sample Preparation Kit. The cobas z 480 analyzer is used for automated amplification and detection.
P150044Roche Molecular Systems, Inc.4300 Hacienda DrivePleasantonCA945882722.0Somatic gene mutation detection systemcobas EGFR MUTATION TEST v2OWDPATrue2015-11-232016-09-2816M-29732016-10-10APCBThe cobas EGFR Mutation Test v2 is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived from EDTA anti-coagulated peripheral whole blood.The test is indicated as a companion diagnostic to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 below in accordance with the approved therapeutic product labeling:Table 1Drug FFPET PlasmaTARCEVA (erlotinib) Exon 19 deletions and L858R Exon 19 deletions and L858RTAGRISSO (osimertinib) 790M T790M*Patients with positive cobas EGFR Mutation Test v2 test results using plasma specimens for the presence of the EGFR mutations listed above are eligible for treatment with the corresponding drug as indicated in Table 1 (see Note* for T790M). Patients who are negative for these mutations by this test should be reflexed to routine biopsy and testing for EGFR mutations with the FFPET sample type. *The efficacy of TAGRISSO (osimertinib) has not been established in the EGFR T790M plasma-positive, tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore, testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.Drug safety and efficacy have not been established for the EGFR mutations listed in Table 2 below that are also detected by the cobas EGFR Mutation Test v2: Table 2Drug FFPET PlasmaTARCEVA (erlotinib) G719X, exon 20 insertions, T790M, S768I and L861Q G719X, exon 20 insertions, T790M, S768I and L861QTAGRISSO (osimertinib) G719X, exon 19 deletions, L858R, exon 20 insertions, S768I, and L861Q G719X, exon 19 deletions, L858R, exon 20 insertions, S768I, and L861QFor manual sample preparation, FFPET specimens are processed using the cobas DNA Sample Preparation Kit and plasma specimens are processed using the cobas cfDNA Sample Preparation Kit. The cobas z 480 analyzer is used for automated amplification and detection.
P150027DAKO NORTH AMERICA, INC.6392 VIA REALCARPINTERIACA93013Immunohistochemistry assay, antibody, programmed death-ligand 1PD-L1 IHC 28-8 pharmDxPLSPAFalse2015-08-042016-01-2316M-08032016-03-03APCBAPPROVAL FOR THE PD-L1 IHC 28-8 PHARMDX. THIS DEVICE IS INDICATED FOR THE FOLLOWING:PD-L1 IHC 28-8 PHARMDX IS A QUALITATIVE IMMUNOHISTOCHEMICAL ASSAY USING MONOCLONAL RABBIT ANTI-PD-L1, CLONE 28-8 INTENDED FOR USE IN THE DETECTION OF PD-L1 PROTEIN IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) NON-SQUAMOUS NON SMALL CELL LUNG CANCER (NSCLC) AND MELANOMA TISSUE USING ENVISION FLEX VISUALIZATION SYSTEM ON AUTOSTAINER LINK 48. PD-L1 PROTEIN EXPRESSION IS DEFINED AS THE PERCENTAGE OF TUMOR CELLS EXHIBITING POSITIVE MEMBRANE STAINING AT ANY INTENSITY. PD-L1 EXPRESSION AS DETECTED BY PD-L1 IHC PHARMDX IN NONSQUAMOUS NSCLC MAY BE ASSOCIATED WITH ENHANCED SURVIVAL FROM OPDIVO (NIVOLUMAB).POSITIVE PD-L1 STATUS AS DETERMINED BY PD-L1 IHC 28-8 PHARMDX IN MELANOMA IS CORRELATED WITH THE MAGNITUDE OF THE TREATMENT EFFECT ON PROGRESSION-FREE SURVIVAL FROM OPDIVO.
P940022ADVANCED BIONICS CORP.12740 SAN FERNANDO RD.SYLMARCA91342Implant, cochlearCLARION(TM) MULTI-STRATEGY COCHLEAR IMPLANTMCMENFalse1994-06-301996-03-2296M-04901996-12-27APCBAPPROVAL FOR THE CLARION MULTI-STRATEGY COCHLEAR IMPLANT FOR USE IN AN ADULT POPLUATION
P810005CIBA VISION CARE11460 JOHNS CREEK PKWY.DULUTHGA301361518.0Lenses, soft contact, extended wearWEICON (R) (TEFILICON) HYDROPHILIC CONTACT LENSLPMOPFalse1981-02-201981-09-2481M-03171981-11-03APCB
P030012HOLOGIC, INC.35 CROSBY DR.BEDFORDMA1730Lung computed tomography system, computer-aided diagnosisIMAGECHECKER CT CAD SOFTWARE SYSTEMNRRRAFalse2003-04-162004-07-0804M-03232004-07-22APCBAPPROVAL FOR THE IMAGECHECKER CT CAD SOFTWARE SYSTEM - MODEL LN-1000. THIS SOFTWARE SYSTEM IS INDICATED TO ASSIST RADIOLOGISTS IN THE DETECTION OF SOLID PULMONARY NODULES DURING REVIEW OF MULTIDETECTOR CT (MDCT) SCANS OF THE CHEST. IT IS INTENDED TO BE USED AS AN ADJUNCT, ALERTING THE RADIOLOGIST - AFTER HIS OR HER INITIAL READING OF THE SCAN - TO REGIONS OF INTEREST (ROIS) THAT MAY HAVE BEEN INITIALLY OVERLOOKED.
P020002HOLOGIC, INC.250 Campus DriveMarlboroughMA1752READER, CERVICAL CYTOLOGY SLIDE, AUTOMATEDTHINPREP (R) IMAGING SYSTEMMNMPAFalse2002-01-072003-06-0603M-03392003-07-30APCBAPPROVAL FOR THE THINPREP IMAGING SYSTEM. THE DEVICE IS INDICATED FOR ASSISTING IN PRIMARY CERVICAL CANCER SCREENING OF THINPREP PAP TEST SLIDES FOR THE PRESENCE OF ATYPICAL CELLS, CERVICAL NEOPLASIA, INCLUDING ITS PRECURSOR LESIONS (LOW GRADE SQUAMOUS INTRAEPITHELIAL LESIONS, HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS, AND CARCINOMA AS WELL AS ALL OTHER CYTOLOGICAL CRITERIA AS DEFINED BY THE 2001 BETHESDA SYSTEM: TERMINOLOGY FOR REPORTING RESULTS OF CERVICAL CYTOLOGY.
P160009iCAD Inc98 Spitbrook Road, Suite 100NashuaNH3062Analyzer, medical imagePowerLook Tomo Detection SoftwareMYNRAFalse2016-04-052017-03-2417M-19502017-03-29APRLApproval for the iCAD PowerLook Tomo Detection Software is a computer-assisted detection (CAD) software device intended to be used concurrently by radiologists while reading GE Senoclaire breast tomosynthesis exams. The system detects up to five soft tissue densities (masses, architectural distortions and asymmetries) in the 3D tomosynthesis images. The detections are blended with the standard 2D synthetic image and the CAD-enhanced 2D synthetic image is viewed on a mammography review workstation.The CAD-enhanced 2D synthetic image assists radiologists in identifying densities (masses, architectural distortions and asymmetries) that may be confirmed or dismissed by the radiologist in the digital breast tomosynthesis (DBT) images.
P010025HOLOGIC, INC.36 Apple Ridge RoadDanburyCT6810Full field digital, system, x-ray, mammographicLORAD DIGITAL BREAST IMAGERMUERAFalse2001-04-302002-03-1502M-01732002-04-25APRLAPPROVAL FOR THE LORAD DIGITAL BREAST IMAGER. THE DEVICE GENERATES DIGITAL MAMMOGRAPHIC IMAGES THAT CAN BE USED FOR SCREENING AND DIAGNOSIS OF BREAST CANCER. IT IS INTENDED FOR USE IN THE SAME CLINICAL APPLICATIONS AS TRADITIONAL SCREEN-FILM MAMMOGRAPHIC SYSTEMS.